据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

证券日报网讯 1月23日，万孚生物发布公告称，公司第五届董事会第二十次会议审议通过，补选王菊芳 女士为独立董事、选举汪洋先生为非独立董事，并同步调整董事会四个专门委员会组成，任期均至第五 届董事会届满。 （编辑 丛可心） ...

董事会于近日收到独立董事段朝晖先生提交的书面辞职报告，段朝晖先生 因个人工作原因申请辞去公司第五届董事会独立董事职务，同时辞去董事会薪 酬与考核委员会主任委员、董事会战略委员会委员职务，其辞职后将不再担任 公司任何职务。段朝晖先生上述职务原定任期为自第五届董事会选举完成之日 至 2027 年 6 月 13 日。 鉴于段朝晖先生的离任将导致薪酬与考核委员会中独立董事所占比例不符 合法律法规和公司章程的规定，根据《公司法》《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》和《公司章程》的有关规定，段 朝晖先生的辞职将在股东会选出新任独立董事后生效，在此之前段朝晖先生将 继续履职。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于补选公司第五届董事会独立董事和选举非独立董 事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术 ...

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2026 年第二次临时股东会的 法律意见书 二零二六年一月 | 北京总部 | 电话: | (86-10) 8519-1300 | 上海分所 | 电话: | (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: | (86-10) 8519-1350 | | 传真: | (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: | (86-571) 2689-8188 | 成都分所 | 电话: | (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: | (86 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-009 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 2026 年第二次临时股东会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有 公司 5%以上股份的股东以外的其他股东。 一、股东会的召开和出席情况 广州万孚生物技术股份有限公司（以下简称"公司"）2026 年第二次临时股 东会于 2026 年 1 月 23 日 14:00 在公司会议室召开。本次股东会由公司第五届董 事会召集，第五届董事会第二十次会议审议通过了召开本次临时股东会的议案。 会议通知已于 2026 年 1 月 7 日在中国证监会指定的信息披露网站公告。本次股 东会由公司董事会召集，董事长王继华女士主持，公 ...

Core Insights - The company focuses on innovation as a driving force for business development and is leveraging AI's transformative impact on healthcare, particularly in laboratory diagnostics and digital pathology [2][3] - The company plans to enhance its AI investments through mergers and acquisitions, as well as a combination of B2B and B2C strategies, aiming to create a valuable ecosystem in the AI healthcare sector [2][3] Group 1: Business Strategy and AI Integration - Since its listing in 2015, the company has been integrating AI into its operations, particularly in the digital pathology sector, and has established a leadership position in ultrasound imaging [2] - The company has developed a multi-modal diagnostic framework that includes imaging, pathology, and laboratory diagnostics, enhancing its brand influence and operational efficiency through AI applications [2] - The company aims to achieve more regulatory approvals and breakthroughs in its business model to become a leading player in the domestic AI healthcare market [3] Group 2: Financial Outlook and Performance - The company anticipates a decline in its profit statement for 2025 due to strategic adjustments, including the divestment of risk assets and a focus on improving operational quality [3] - Despite the expected downturn in 2025, the company is optimistic about a recovery in domestic business in 2026, supported by a low base from the previous year, and has positive growth expectations for its overseas operations [3] - The company has launched the "Wanfubio Smart Inspection" AI platform, which features multiple AI applications for various medical scenarios, contributing to growth in the consumer segment through its health app [3]

Core Insights - Wanfu Bio has established an AI medical ecosystem since 2018, focusing on "mergers and acquisitions + hospital end + consumer end" to become a leading player in China's AI medical field [1][2] Group 1: Investment and Partnerships - Wanfu Bio's investment in Saiweisen Medical Technology led to the acquisition of China's first Class III medical device registration for cervical cancer cell digital pathology diagnostic software, expected to be operational by February 2025 [1] - The company also invested in Shenzhen Shengqiang Technology, which aims to create intelligent pathology solutions through hardware and software integration, enhancing the digital workflow in hospital pathology departments [1] - Medical technology company Yizhun Intelligent, backed by Zhongfu Yide Industrial Fund, has received the first and second Class III certifications for breast X-ray and thyroid nodule ultrasound AI detection software, respectively [1] Group 2: Business Development and Innovations - Wanfu Bio has launched the "Wanfu Smart Inspection" AI platform for hospitals, featuring multiple AI applications in various medical scenarios, including coagulation diseases and tumors [2] - The company has introduced the Wanfu Health mini-program for consumers, which uses AI to automatically identify results from respiratory, digestive, and blood infectious disease tests, supporting personal health record creation [2] - Future plans include enhancing multi-modal and multi-omics development in diagnostics, leveraging years of experience in laboratory testing to improve grassroots testing capabilities in collaboration with its invested companies [2]

万孚生物介绍，公司自2018年起前瞻性地布局AI医疗领域，通过"并购+院端+C端"三位一体的策略，构 建了全面的AI医疗生态系统。公司通过战略投资、基金参股等方式，成功将赛维森医疗科技、生强科 技及医准智能三家在影像、病理和实验室诊断领域各具优势的企业纳入其生态圈。其中，赛维森医疗科 技于2025年2月获得了国内首张宫颈癌细胞数字病理图片辅助诊断软件三类医疗器械注册证，标志着其 在病理AI领域的领先地位。医准智能则在CT影像和超声影像AI检测软件方面表现卓越，目前已持有6张 三类证，其产品在多家医院实现商业化应用。生强科技则致力于打造病理数智化全链路解决方案，推动 医院病理科数字化工作流程的升级。这些战略投资不仅完善了万孚生物在多模态诊断领域的拼图，更形 成了强大的协同效应。 主业方面，万孚生物自身的海外业务同样展现出强劲的增长势头。记录表信息显示，公司基于发光、荧 光、胶体金三大免疫平台，在发展中国家与发达国家市场均取得重要突破。特别是在急诊场景和美国市 场的呼吸道三联检产品，预计将为2026年的海外业务带来显著增量。 公司表示，未来诊断将朝着多模态、多组学的方向发展，AI技术在其中的应用空间巨大。通过与生 ...

Core Viewpoint - Wanfu Biological experienced a stock price increase of 12.81% year-to-date, with a notable rise of 4.11% in the last five trading days, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders was 134 million yuan, down 69.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.213 billion yuan, with 601 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wanfu Biological was 42,400, a decrease of 5.59% from the previous period. The average number of circulating shares per shareholder increased by 5.94% to 10,160 shares [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.1927 million shares, a reduction of 1.3623 million shares from the previous period. The Southern Zhongzheng 1000 ETF held 2.6442 million shares, down by 20,900 shares [3]. Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary services (0.04%) [1]. Market Position - Wanfu Biological is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics. The company is associated with various concept sectors, including avian influenza drugs, assisted reproduction, anti-influenza, gene sequencing, and the pet economy [1].

Group 1: Company Overview and AI Medical Layout - Guangzhou Wanfu Biological Technology Co., Ltd. has been investing in AI medical since 2018, aiming to become a leading enterprise in the domestic AI medical field through a "merger + hospital end + consumer end" strategy [2][4] - The company’s investment in Saiweisen Medical Technology led to the first domestic Class III medical device registration for cervical cancer cell digital pathology software in February 2025 [2][3] - Wanfu has developed the "Wanfu Smart Inspection" AI platform for hospitals, which has been implemented in various medical scenarios [3][4] Group 2: Investment and Collaboration - The company collaborates with Saiweisen, Shengqiang, and Yizhun Intelligent to enhance diagnostic capabilities through software and hardware integration [4][5] - The partnership aims to leverage each company's strengths in imaging, pathology, and laboratory testing to capture opportunities in AI applications [4][5] Group 3: Product Development and Market Position - Saiweisen has received the first Class III certification for AI-assisted diagnosis in gynecology, with ongoing clinical trials for non-gynecological applications [5][6] - Shengqiang Technology has developed a comprehensive digital pathology solution, covering approximately 2,000 hospitals domestically and 12 overseas regions [7][8] - Yizhun Intelligent holds 15 Class II and 6 Class III certifications, with a focus on ultrasound AI technology, which is more complex than radiology AI [9][10] Group 4: Market Trends and Future Outlook - The introduction of new policies is expected to significantly increase the volume of digital slices in the pathology market, creating substantial market capacity [8][9] - The AI medical sector is projected to grow rapidly, with a focus on enhancing brand influence and operational efficiency through innovative AI applications [10][11] - The company anticipates a recovery in domestic business in 2026, supported by overseas growth driven by various platforms [12][13]